Anti-Inflammatory and Antiatherogenic Role of BMP Receptor II in Endothelial Cells
Authors:
- 1 June 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 33 (6) , 1350-1359
Abstract
Objective—: Atherosclerosis is an inflammatory disease with multiple underlying metabolic and physical risk factors. Bone morphogenic protein 4 (BMP4) expression is increased in endothelium in atherosclerosis-prone regions and is known to induce endothelial inflammation, endothelial dysfunction, and hypertension. BMP actions are mediated by 2 different types of BMP receptors (BMPRI and BMPRII). Here, we show a surprising finding that loss of BMPRII expression causes endothelial inflammation and atherosclerosis. Approach and Results—: Using BMPRII siRNA and BMPRII +/− mice, we found that specific knockdown of BMPRII, but not other BMP receptors (Alk1, Alk2, Alk3, Alk6, ActRIIa, and ActRIIb), induced endothelial inflammation in a ligand-independent manner by mechanisms mediated by reactive oxygen species, nuclear factor-KappaB, and reduced nicotinamide adenine dinucleotide phosphate oxidases. Further, BMPRII +/− ApoE −/− mice developed accelerated atherosclerosis compared with BMPRII +/+ ApoE −/− mice. Interestingly, we found that multiple proatherogenic stimuli, such as hypercholesterolemia, disturbed flow, prohypertensive angiotensin II, and the proinflammatory cytokine (tumor necrosis factor-α), downregulated BMPRII expression in endothelium, whereas antiatherogenic stimuli, such as stable flow and statin treatment, upregulated its expression in vivo and in vitro. Moreover, BMPRII expression was significantly diminished in human coronary advanced atherosclerotic lesions. Also, we were able to rescue the endothelial inflammation induced by BMPRII knockdown by overexpressing the BMPRII wild type, but not by the BMPRII short form lacking the carboxyl-terminal tail region. Conclusions—: These results suggest that BMPRII is a critical, anti-inflammatory, and antiatherogenic protein that is commonly targeted by multiple pro- and antiatherogenic factors. BMPRII may be used as a novel diagnostic and therapeutic target in atherosclerosis.Keywords
This publication has 49 references indexed in Scilit:
- BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAHHuman Molecular Genetics, 2012
- Controlling cell fate by bone morphogenetic protein receptorsMolecular and Cellular Endocrinology, 2003
- Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Stimulates an Inflammatory ResponseJournal of Biological Chemistry, 2003
- Inflammation in atherosclerosisNature, 2002
- Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein ReceptorCirculation, 2002
- Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic PlaquesArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- How cells read TGF-β signalsNature Reviews Molecular Cell Biology, 2000
- Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertensionNature Genetics, 2000
- BMP Type II Receptor Is Required for Gastrulation and Early Development of Mouse EmbryosDevelopmental Biology, 2000
- Lessons From Sudden Coronary DeathArteriosclerosis, Thrombosis, and Vascular Biology, 2000